4 unknown, 3 recruiting, 2 completed, 1 active not recruiting. 4 Phase 2, 3 Phase 3, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 1, Unknown 1 |
| Phase 3 | 3 | Unknown 2, Recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Chemoradiotherapy, Adjuvant: new trials by email Literature Review of Chemoradiotherapy, Adjuvant trials Research Report on Chemoradiotherapy, Adjuvant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Active Surveillance vs Adjuvant Chemoradiotherapy for Locally Resected Intermediate-Risk T1 Rectal Cancer Active surveillance, Adjuvant chemoradiotherapy - Rectal Cancer | Not applicable | Recruiting | Medical University of Gdansk | 480 | 2026-06-14 | 2026-06-25 |
| Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC) Adjuvant chemoradiotherapy, Adjuvant chemotherapy - Pancreatic Cancer | Phase 3 | Recruiting | Changhai Hospital | 770 | 2024-08-06 | 2025-02-04 |
| Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal Cancer Adjuvant Immunoradiotherapy (ARM1) and Adjuvant Immunotherapy (ARM1B), Adjuvant chemoradiotherapy - Esophageal Cancer | Phase 1 | Active not recruiting | University of Manitoba | 11 | 2023-03-01 | 2026-05-11 |
| Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC Nab-paclitaxel, cisplatin and Pembrolizumab combination, surgery, Adjuvant Chemoradiotherapy - Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | Guangdong Provincial People's Hospital | 86 | 2022-03-01 | 2025-07-01 |
| Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study Follow-up only, Adjuvant chemotherapy, Adjuvant chemoradiotherapy - Resectable Pancreatic Cancer, Adjuvant Chemoradiotherapy | Unknown | Shanghai Zhongshan Hospital | 400 | 2020-01-01 | 2021-02-04 | |
| CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer Nivolumab, Surgery, Radiotherapy, Nivolumab, Surgery, Chemoradiotherapy - Squamous Cell Carcinoma of the Oral Cavity | Phase 2 | Completed | The Clatterbridge Cancer Centre NHS Foundation Trust | 21 | 2019-05-10 | 2025-02-25 |
| Adujvant CT+CRT vs Adujvant CT After D2 Resection for Locally Advanced Proximal Gastric Adenocarcinoma Adjuvant Chemoradiotherapy, Adjuvant Chemotherapy - Gastric Adenocarcinoma | Phase 3 | Unknown | Zhejiang Cancer Hospital | 408 | 2019-03-11 | 2019-06-04 |
| Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA], adjuvant radiochemotherapy - HNSCC | Phase 2 | Completed | University of Leipzig | 211 | 2018-08-06 | 2026-02-17 |
| Rectal Preserving Treatment for Early Rectal Cancer. A Multi-centred Randomised Trial of Radical Surgery Versus Adjuvant Chemoradiotherapy After Local Excision for Early Rectal Cancers Adjuvant chemoradiotherapy, Additional TME surgery, capecitabine - Rectal Cancer | Phase 3 | Unknown | Amsterdam UMC, location VUmc | 302 | 2015-10-01 | 2020-05-21 |
| Neoadjuvant Versus Adjuvant Therapy in Treating Resectable Thoracic Esophageal Cancer Neoadjuvant chemoradiotherapy, Adjuvant chemoradiotherapy - Esophageal Cancer | Phase 2 | Unknown | Zhejiang Cancer Hospital | 60 | 2011-10-01 | 2013-05-14 |
Squamous Cell Carcinoma of Head and Neck (3) · Esophageal Neoplasms (2) · Rectal Neoplasms (2) · Carcinoma, Squamous Cell (1) · Head and Neck Neoplasms (1) · Pancreatic Neoplasms (1)
Zhejiang Cancer Hospital (2) · Amsterdam UMC, location VUmc (1) · Changhai Hospital (1) · Guangdong Provincial People's Hospital (1) · Medical University of Gdansk (1) · Shanghai Zhongshan Hospital (1) · The Clatterbridge Cancer Centre NHS Foundation Trust (1) · University of Leipzig (1) · University of Manitoba (1)
China (5) · Canada (1) · France (1) · Germany (1) · Netherlands (1) · Poland (1) · United Kingdom (1)
Andreas Dietz, Prof. Dr. (1) · Biniam Kidane (1) · Huojun Zhang, M.D. (1) · Joseph Sacco, MBChB (1) · Weimin Mao, MD (1) · Xiangdong Cheng (1)
PMID 27439975, PMID 34717717, PMID 40583350, PMID 42202843
2017 (1)